The minister emphasized the importance of public awareness campaigns to educate citizens about preventive measures amid changing weather conditions that increase the risk of vector-borne and water-borne diseases.

He instructed health officials to strengthen sanitation drives, ensure adequate availability of medicines, and maintain strict disease surveillance systems across urban and rural areas. The minister also directed district health officers to coordinate with local bodies to prevent mosquito breeding and safeguard public health.

The post Telangana Health Minister Reviews Seasonal Disease Control Measures in Hyderabad appeared first on India Podcast.

Lawmakers and locals criticized the district health authorities for weak preventive measures and insufficient healthcare facilities. Social workers said anti-mosquito campaigns have been largely symbolic, and the district lacks a dedicated dengue control unit. Panjgur, with about one million residents, has no effective system to fight dengue.

National Party leader Rahmat Saleh Baloch urged the provincial government, WHO, and UNICEF to send medical teams immediately. He also requested declaring Panjgur a dengue-affected district, launching fumigation campaigns, and improving hospital facilities. Civil society groups called for a dedicated dengue treatment unit at Panjgur Hospital.

Meanwhile, Khyber Pakhtunkhwa authorities declared a Chikungunya outbreak in Peshawar’s Sufaid Dheri area after 16 cases were detected. The cases appeared in zones with high dengue incidence. Health officials confirmed they are taking prompt action to contain the viral fever and protect residents.

The post Dengue Outbreak Hits Pakistan’s Panjgur District appeared first on India Podcast.

AdFalciVax specifically targets Plasmodium falciparum, the deadliest malaria parasite. It not only protects individuals from infection but also prevents transmission through mosquitoes, breaking the disease cycle. Health experts believe this vaccine could be a turning point in India’s fight against malaria.

Pre-clinical studies revealed strong immune responses and long-lasting protection. Unlike traditional vaccines, AdFalciVax offers broader coverage and remains stable at room temperature for up to nine months. This feature makes it easier to transport and store in remote areas where refrigeration is often unavailable.

The vaccine is produced using the safe bacterium Lactococcus lactis. For nationwide production, ICMR has licensed five companies: Indian Immunologicals Limited, TexInvention Lifecare, Panacea Biotech, Biological E Limited, and Zydus Lifesciences. The first batch is expected to be available by the end of this year, raising hopes for large-scale malaria control.

The post ICMR Develops Indigenous Malaria Vaccine AdFalciVax appeared first on India Podcast.